1071517-39-9
Chemical Structure
Setrobuvir
Synonym(s): ANA598
- CAS No.: 1071517-39-9
- Formula:C25H25FN4O6S2
- Molecular Weight:560.62
IUPAC Name: N-(3-((4aR,5S,8R,8aS)-1-(4-fluorobenzyl)-4-hydroxy-2-oxo-1,2,4a,5,6,7,8,8a-octahydro-5,8-methanoquinolin-3-yl)-1,1-dioxido-2H-benzo[e][1,2,4]thiadiazin-7-yl)methanesulfonamide
InChIKey: DEKOYVOWOVJMPM-RLHIPHHXSA-N
SMILES: CS(=O)(NC1=CC=C(C2=C1)N=C(C3=C(O)[C@]4([H])[C@@](C5)([H])CC[C@@]5([H])[C@]4([H])N(CC6=CC=C(F)C=C6)C3=O)NS2(=O)=O)=O
Biological Activity: Setrobuvir (ANA598) is an orally active non-nucleosidic HCV NS5B polymerase inhibitor. ANA-598 inhibits both de novo RNA synthesis and primer extension, with IC50s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS-CoV-2 RdRp and induces RdRp inhibition[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Setrobuvir | 99.98% | Setrobuvir (ANA598) is an orally active non-nucleosidic HCV NS5B polymerase inhibitor. ANA-598 inhibits both de novo RNA synthesis and primer extension, with IC50s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS-CoV-2 RdRp and induces RdRp inhibition. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Yi G, et al. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob Agents Chemother. 2012;56(2):830‐837. [Content Brief]
- [2]. Elfiky AA. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silicoperspective [published online ahead of print, 2020 May 6]. J Biomol Struct Dyn. 2020;1‐9. [Content Brief]
